Format

Send to

Choose Destination
Anticancer Res. 2014 Jan;34(1):295-9.

Zinc supplementation improves anticancer activity of monocytes in type-2 diabetic patients with metabolic syndrome.

Author information

1
Department of Physiology and Pharmacology, Faculty of Pharmaceutical Sciences, and Cell-based Drug and Health Product Development Research Unit, Chulalongkorn University, Phyathai road, Pathumwan, Bangkok, 10330 Thailand. pithi_chan@yahoo.com.

Abstract

BACKGROUND:

Transmembrane tumor necrosis factor (TNF)-α, found on monocytes, is a body's key defense against cancer. In patients with type 2 diabetes mellitus (DM) and metabolic syndrome, immunity is suppressed, resulting in a high risk of several inflammatory disorders and cancer.

PATIENTS AND METHODS:

Seventeen patients with type 2 DM and metabolic syndrome were supplemented with either 30 mg of elemental zinc/day or placebo for eight weeks. Transmembrane TNF-α-expressing monocytes and lymphocytes, and plasma TNF-α levels were analyzed before and after supplementation.

RESULTS:

The present study revealed that zinc supplementation significantly increased the proportion of monocytes expressing transmembrane TNF-α. While the plasma TNF-α levels and TNF-α expressing lymphocytes were not significantly altered in the zinc-treated and placebo groups, higher proportion of TNF-α bound monocytes were observed in the zinc-treated group.

CONCLUSION:

Because functional transmembrane TNF-α was shown to be implicated in defense mechanisms, these findings suggest that zinc supplementation may benefit immune response against cancer in patients with DM and metabolic syndrome.

KEYWORDS:

Metabolic syndrome; monocyte; transmembrane TNF-α; type 2 diabetes; zinc

PMID:
24403477
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center